Generate Biomedicines (NASDAQ:GENB) Trading Up 7.9% – Still a Buy?

Generate Biomedicines Inc (NASDAQ:GENB)’s stock price traded up 7.9% during trading on Monday . The company traded as high as $16.15 and last traded at $15.6410. Approximately 225,803 shares were traded during mid-day trading, a decline of 63% from the average daily volume of 616,535 shares. The stock had previously closed at $14.49.

Analyst Upgrades and Downgrades

Several analysts have commented on GENB shares. The Goldman Sachs Group assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 target price for the company. Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright raised their price target on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Finally, Guggenheim initiated coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $30.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Generate Biomedicines Stock Performance

The stock has a 50-day simple moving average of $13.38.

Generate Biomedicines (NASDAQ:GENB) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.